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Cardiac glycosides, also known as cardiotonic steroids, are a group of natural products that share a steroid-like structure with an
unsaturated lactone ring and the ability to induce cardiotonic effects mediated by a selective inhibition of the Na+/K+-ATPase.
Cardiac glycosides have been used for many years in the treatment of cardiac congestion and some types of cardiac arrhythmias.
Recent data suggest that cardiac glycosides may also be useful in the treatment of cancer.These compounds typically inhibit cancer
cell proliferation at nanomolar concentrations, and recent high-throughput screenings of drug libraries have therefore identified
cardiac glycosides as potent inhibitors of cancer cell growth. Cardiac glycosides can also block tumor growth in rodent models,
which further supports the idea that they have potential for cancer therapy. Evidence also suggests, however, that cardiac glycosides
may not inhibit cancer cell proliferation selectively and the potent inhibition of tumor growth induced by cardiac glycosides in
mice xenografted with human cancer cells is probably an experimental artifact caused by their ability to selectively kill human cells
versus rodent cells.This paper reviews such evidence and discusses experimental approaches that could be used to reveal the cancer
therapeutic potential of cardiac glycosides in preclinical studies.
1. Introduction
Cardiac glycosides, also known as cardiotonic steroids, are
natural products with a steroid-like structure and an unsat-
urated lactone ring. They usually contain sugar moieties
in their structure and have cardiotonic activity. Cardiac
glycosides containing the lactone 2-furanone are known as
cardenolides and those containing the lactone 2-pyrone are
known as bufadienolides (Figure 1). Most cardiac glycosides
(e.g., digitoxin, digoxin, ouabain, and oleandrin) have been
isolated from plants, including Digitalis purpurea, Digitalis
lanata, Strophanthus gratus, and Nerium oleander. Some
cardiac glycosides have also been found in amphibians and
mammals, including digoxin, ouabain, bufalin, marinobufa-
genin, and telecinobufagin. Several cardiac glycosides are
used in cardiology for the treatment of cardiac congestion
and some types of cardiac arrhythmias. The mechanism by
which these drugs affect cardiac contractility is thought to
be mediated by a highly specific inhibition of the Na+/K+-
ATPase pump [1–3].
Over the years, several reports have suggested that cardiac
glycosides may have an anticancer utilization (reviewed in
[4–13]). In vitro and ex vivo experiments have revealed that
some cardiac glycosides (e.g., digitoxin) induce potent and
selective anticancer effects [4, 14, 15], whichmay occur at con-
centrations commonly found in the plasma of patients treated
with these drugs [16]. Recent high-throughput screenings
of drug libraries have identified several cardiac glycosides
(e.g., digoxin, ouabain, and bufalin) as potent inhibitors of
cancer cell growth [17–19].These cardiac glycosides were also
able to block tumor growth in mice xenotransplanted with
human cancer cells, further supporting the idea that these
compounds should be evaluated in cancer patients [17–19].
The cardiac drugs digitoxin and digoxin, the semisynthetic
cardiac glycoside UNBS1450, and two extracts from the plant
Nerium oleander have entered clinical trials for the treatment
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Figure 1: Chemical structure of cardiac glycosides. The basic skeletons of cardenolides and bufadienolides and the structures of the
cardenolide digitoxin and the bufadienolide bufalin are shown.
of cancer (see http://clinicaltrials.gov/ and ref. [6, 7, 10, 20,
21]).
Research results also suggest, however, that cardiac gly-
cosides may not inhibit cancer cell proliferation selectively
in particular types of cancer [22–24] and the potent inhi-
bition of tumor growth induced by cardiac glycosides in
mice xenografted with human cancer cells is probably an
experimental artifact caused by their ability to selectively
kill human cells versus rodent cells rather than by their
ability to selectively kill human cancer cells versus human
normal cells [24–26]. After reviewing such evidence, this
paper discusses experimental approaches that can be used to
reveal the cancer therapeutic potential of cardiac glycosides
in preclinical studies.
2. Possible Misinterpretation of
Data from Preclinical Studies
Inhibition of cancer cell proliferation at low concentrations
and inhibition of tumor growth in animal models are the
most common parameters used by researchers to assess the
therapeutic potential of drug candidates in preclinical studies.
Based on this approach, researchers have proposed cardiac
glycosides as candidates for evaluation in clinical trials. This
section of the paper reviews evidence indicating that this
approach may be inadequate to reveal the cancer therapeutic
potential of cardiac glycosides.
2.1. Inhibition of Cancer Cell Proliferation at Low Concen-
trations Does Not Reliably Predict Therapeutic Potential. The
key feature of an efficient anticancer drug candidate is its
ability to kill (or to inhibit the proliferation of) human cancer
cells at concentrations that do not significantly affect human
nonmalignant cells. If the anticancer drug candidate does not
have this feature, it does not really matter whether or not it
can kill cancer cells at low concentrations. The reason is that
the drug concentrations required to kill the tumor cells of
cancer patients would also cause the death of their normal
cells and, therefore, would be lethal to these patients. It is
important to note that the therapeutic potential of a drug able
to kill cancer cells at a concentration of 1 millimolar without
significantly affecting nonmalignant cells at a concentration
of 10 millimolar is probably higher than that of a drug that
kills both cancer and nonmalignant cells at a concentration
of 1 nanomolar.
Cancer researchers do not commonly use human non-
malignant cells to assess the therapeutic potential drug
candidates. Possible reasons are that they may consider
that the inhibition of human cancer cell proliferation at
low concentrations is an adequate parameter to predict
therapeutic potential or they prefer using animal models
instead. Researchers typically use mice xenotransplanted
with human cancer cells to reveal whether their drug can-
didates inhibit cancer cell growth selectively. If their drugs
inhibit tumor growth in these models without killing or
significantly affecting the animals, they assume that their
drugs also inhibit the proliferation of human cancer cells
without significantly affecting that of human nonmalignant
cells. Following this approach, researchers have proposed
several cardiac glycosides as candidates for clinical testing in
cancer patients [17–19, 27, 28].
Several research groups have evaluated the cancer thera-
peutic potential of cardiac glycosides by using human cancer
cells and humannonmalignant cells. For instance, we recently
observed that the cytotoxicity of digitoxin, digoxin, and
ouabain in breast cancer cells (MCF-7) and melanoma cells
(UACC-62)was similar than that in nonmalignant breast cells
(MCF-10) and nonmalignant skin cells (VH-10) [24]. Clifford
and Kaplan [23] have recently reported that human breast
cancer cells were even more resistant to ouabain, digitoxin,
and bufalin toxicity than human nonmalignant breast cells.
Evidence has also shown, however, that digitoxin, digoxin,
and ouabain were approximately 10 times more cytotoxic
against human A549 lung cancer cells than against human
MRC-5 nonmalignant lung cells (5–8 nM versus 29–75 nM)
[24]. Ex vivo experiments, using cells from adult patients
with B-precursor or T-acute lymphoblastic leukemia (ALL),
acute myeloid leukemia (AML), and chronic lymphocytic
leukemia (CLL), as well as peripheral blood mononuclear
cells from healthy donors, have also shown that digitoxin
(but not ouabain) induced selective cytotoxicity (approxi-
mately 7-fold) in cells from patients with T- and B-precursor
ALL [15]. In brief, although cardiac glycosides can inhibit
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the proliferation of cancer cells at very low concentrations
(nM), they usually inhibit the proliferation of human nonma-
lignant cells at similar concentrations; this strongly suggests
that their potential for cancer therapy is low. In contrast,
specific cardiac glycosides (e.g., digitoxin) can inhibit the
proliferation of particular types of cancer cells (e.g., lung can-
cer and acute lymphoblastic leukemia) at concentrations that
do not significantly affect human nonmalignant cells; these
cardiac glycosides may have cancer therapeutic potential.
2.2. The Anticancer Activity of Cardiac Glycosides in Mice
Xenografted with Human Cancer Cells Is Probably an Exper-
imental Artifact. Several cardiac glycosides that are equally
toxic to human cancer cells and human nonmalignant cells
have shown potent anticancer effects in animal models.
For instance, Clifford and Kaplan observed that human
nonmalignant breast cells were more sensitive than human
breast cancer cells (e.g., MDA-MB-231) to the cytotoxic
effects of bufalin [23], and it has recently been reported
that bufalin reduces tumor growth in mice xenotransplanted
with human MDA-MB-231 breast cancer cells [19]. These
apparent controversies can be explained by the ability of
cardiac glycosides to kill human cells at concentrations much
lower (approximately 100–1000 fold) than those required to
kill rodent cells [24, 29].
Gupta and colleagues [29] evaluated some time ago the
cytotoxicity of numerous cardiac glycosides (i.e., ouabain,
digitoxin, digoxin, convallatoxin, SC4453, bufalin, gitaloxin,
digoxigenin, actodigin, oleandrin, digitoxigenin, gitoxin,
strophanthidin, gitoxigenin, lanatosides A, B, and C, alpha-
and beta-acetyl digoxin, and alpha- and beta-methyl digoxin)
against a number of independent cell lines established
from human, monkey, mouse, Syrian hamster, and Chinese
hamster. The authors observed that all cardiac glycosides
exhibited greater than 100-fold higher toxicity towards the
human and monkey cells in comparison to the rodent cells
(mouse, Syrian hamster, and Chinese hamster). They also
provided strong evidence that the species-related differences
in sensitivity to cardiac glycosides were mediated by the
Na+/K+-ATPase enzyme. They observed that the Na+/K+-
ATPase enzyme of rodent cells was inhibited at much higher
concentrations of cardiac glycosides than theNa+/K+-ATPase
of human cells. They also observed a good correlation
between these concentrations and those reported for inhibi-
tion of the Na+/K+-ATPase from isolated heart muscles of
the same species [29]. More recent evidence suggests that
the expression and cellular location of Na+/K+-ATPase alpha
subunits in different types of cells may explain why they are
more or less susceptible to the cytotoxic activity of cardiac
glycosides [30–32].
Several years ago, a PNAS paper reported that digoxin
blocked tumor growth in mice xenotransplanted with several
types of human cancer cells [17]. The authors observed
that digoxin prolonged tumor latency and inhibited tumor
xenograft growth in mice when treatment was initiated
before the implantation of P493-Myc, P493-Myc-Luc, PC3,
and Hep3B cells. Digoxin also arrested tumor growth when
treatment was initiated after the establishment of PC3 and
P493-Myc tumor xenografts [17]. Based on the observations
of Gupta and colleagues [29] and on the plasma levels
of digoxin in cardiac patients, we discussed the fact that
the potent anticancer effects induced by digoxin in mice
harboring human cancer cells [17] were not relevant to the
treatment of human cancer and these anticancer effects were
probably due to interspecies differences in sensitivity [25]. In
other words, the marked reduction in tumor growth induced
by digoxin in mice xenografted with human cancer cells
was probably caused by the ability of cardiac glycosides to
selectively kill human cells versus rodent cells rather than
by their ability to selectively kill cancer cells versus normal
cells. Perne et al. [22] later reported experimental data that
further supported this idea. Despite these and other reports
[24, 26], numerous publications containing this probable
experimental artifact continue to appear in the scientific
literature.
This section of the paper now reviews reports that have
used mice xenotransplanted with human cancer cells to
evaluate anticancer effects of cardiac glycosides (Table 1).
The results of the following reports should probably be
reinterpreted.
Digoxin. Svensson et al. [33] carried out in vitro and in vivo
studies to evaluate the anticancer activity of the cardenolide
digoxin. They studied the effect of digoxin on the growth of
tumor cell lines and primary endothelial cells from different
species. The most sensitive cell lines in vitro were the human
SH-SY5Y and SK-N-AS neuroblastoma cell lines; the IC
50
values were 34 and 22 ng/mL, respectively.They also reported
that digoxin significantly reduced the growth of human SH-
SY5Y neuroblastoma cells xenotransplanted in immunode-
ficient mice. The authors concluded that digoxin might be
a specific neuroblastoma growth inhibitor. The authors also
reported that the in vitro and in vivo anticancer effects of
digoxin were dramatically reduced when the murine Neuro-
2a neuroblastoma cell line was used instead of the human
neuroblastoma cell lines [33]. Zavareh et al. [34] reported
data suggesting that cardiac glycosides were inhibitors of
N-glycan biosynthesis. Since aberrant N-linked glycans are
known to contribute to cancer progression and metastasis,
the authors studied whether digoxin could inhibit cellular
migration and invasion. They used two mouse models of
metastatic cancer in which human PPC-1 prostate cancer
cells were injected into immunodeficient mice. They found
that digoxin reduced distant tumor formation in bothmodels
and concluded that this cardiac glycoside could be a lead
for the development of antimetastasis therapies. As discussed
before, Zhang et al. [17] found that digoxin inhibited hypoxia-
inducible factor 1 (HIF-1), a transcription factor highly
involved in cancer development, and suggested that this
effect might be observed in patients taking this drug. They
also reported that digoxin blocked tumor growth in mice
xenotransplanted with several types of human cancer cells.
These data suggested that digoxin had anticancer potential
[17]. Wong et al. [35] reported data suggesting that digoxin
was a potential antimetastasis compound. They investigated
whether digoxin could reduce metastases in human MDA-
MB-435 tumor-bearing mice. Digoxin blocked metastatic
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Table 1: The antitumor activity of cardiac glycosides in mice xenografted with human cancer cells is probably caused by their ability to
selectively kill human cells versus rodent cells rather than by their ability to selectively kill human cancer cells versus human nonmalignant
cells.
Cardiac
glycoside
Antitumor activity in mice
xenografted with human cancer
cells
Selective cytotoxicity
against human cells
versus rodent cells
Selective cytotoxicity against human cancer cells versus
human nonmalignant cells
Arenobufagin Liver HepG2/ADM [28] N.D. N.D.
Bufalin
Breast MDA-MB-231 [19],
osteosarcoma U2OS/MTX300
[50], and pancreatic Mia Paca-2
[49]
>1000-fold [29]
NO: breast cancer versus breast nonmalignant [23];
10-fold: ovarian cancer versus endometrial
nonmalignant [53]
Bufotalin Liver R-HepG2 [51] >100-fold [54] N.D.
Digitoxin N.D.
>1000-fold [29];
>700-fold [24]
10-fold: lung cancer versus lung nonmalignant [24];
3-fold: lung cancer versus lung nonmalignant [55];
7-fold: ALL versus PBMCs nonmalignant [15]; 4-fold:
AML versus PBMCs nonmalignant [15]; 2-fold: CLL
versus PBMCs nonmalignant [15]; 2-fold: breast cancer
versus breast nonmalignant [24]; NO: breast cancer
versus breast nonmalignant [23]; NO: skin cancer
versus skin nonmalignant [24]
Digoxin
Brain SH-SY5Y [33], brain
SK-N-AS [33], breast
MDA-MB-231 [36, 37], breast
MDA-MB-435 [35], liver Hep3B
[17], prostate PC3 [17], prostate
PPC-1 [34], and transformed
human B-lymphocytes
P493-Myc [17]
>1000-fold [24, 29]
NO: breast cancer versus breast nonmalignant [24]; 8-
fold: lung cancer versus lung nonmalignant [24]; NO:
skin cancer versus skin nonmalignant [24]; 8-fold: brain
cancer versus umbilical vein endothelial nonmalignant
[33]; NO: breast cancer versus umbilical vein
endothelial nonmalignant [33]; NO: colorectal cancer
versus umbilical vein endothelial nonmalignant [33]
Lanatoside C Brain U87 [48] >100-fold [29] N.D.
Ouabain
Brain SH-SY5Y [27], ocular
Y79LUC [39], pancreatic BON1
[40], promyelocytic leukemia
HL-60 [18], and prostate PPC-1
[40]
>1000-fold [24, 29, 44]
NO: breast cancer versus breast nonmalignant [23, 24];
5- fold: lung cancer versus lung nonmalignant [24];
NO: skin cancer versus skin nonmalignant [24]; 2-fold:
ALL versus PBMCs nonmalignant [15]; 2-fold: AML
versus PBMCs nonmalignant [15]; NO: CLL versus
PBMCs nonmalignant [15]
Periplocin Liver Huh-7 [47] and lung A549[46]
>1000-fold [47]∗; NO:
[46]
>1000-fold: liver cancer versus PBMCs nonmalignant
[47]∗
UNBS1450
Brain U373-MG [44], lung A549
[41, 42], lung NCI-H727 [41, 42],
prostate PC-3 [43], and skin
VM-48 [45]
>100-fold [44]
10-fold: brain cancer versus lung and skin
nonmalignant [44]; 100-fold: prostate cancer versus
lung and skin nonmalignant [43]
N.D.: not determined; NO: no selective cytotoxicity; ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; CLL: chronic lymphocytic leukemia;
PBMCs: peripheral blood mononuclear cells; ∗not specified if the PBMCs were human cells or rodent cells (we contacted the authors without success).
niche formation and breast cancer metastasis in the lungs,
and the authors discussed the fact that this effectwas probably
due to inhibition of HIF-1. The most relevant conclusion of
this work was that digoxin might be useful to treat patients
with HIF-1-overexpressing breast cancers [35]. Zhang et al.
[36] observed that digoxin reduced tumor growth and inhib-
ited the metastasis of human MDA-MB-231 breast cancer
cells to the lungs inmice xenograftedwith these cells, without
causing any sign of toxicity in the animals. They concluded
that clinical trials were warranted to investigate whether the
concentrations of digoxin achievable in patients are sufficient
to inhibit tumor growth andmetastases [36]. Schito et al. [37]
reported that HIF-1 promoted lymphatic metastases of breast
cancer and the use of the HIF-1 inhibitor digoxin strongly
decreased tumor growth and blocked lymphangiogenesis and
lymphatic metastasis in mice bearing human breast cancer
cells. The authors suggested that digoxin might be useful to
treat patients with high risk of lymphatic metastases [37].
Gayed et al. [38] observed that specific concentrations of
digoxin inhibited blood vessel formation but not tumor
growth inmice injected with the humanC4-2 prostate cancer
cell line.
Ouabain. Several cardiac glycosides were identified by
Antczak et al. [39] as potent antiretinoblastoma agents in
vitro. One of them, the cardenolide ouabain, induced a drastic
tumor regression in immunodeficient mice injected with
human Y79LUC retinoblastoma cells, without inducing any
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significant toxicity on the host. In light of the results of their
study, the authors proposed that digoxin, which is widely
used in patients with cardiac disease, could be repositioned
for the treatment of retinoblastoma [39]. Simpson et al.
[40] identified the cardiac glycosides ouabain, peruvoside,
digoxin, digitoxin, and strophanthidin as anoikis sensitizers.
Because resistance to anoikis permits cancer cells to survive
in the circulation and improves their metastatic potential,
the authors evaluated inmousemodels of metastasis whether
ouabain could block distant tumor formation.They observed
that ouabain reduced the number of tumors in human PPC-1
prostate cancer cells bearing mice. They also reported that
systemic administration of ouabain decreased the survival
and growth of human PPC-1 prostate cancer cells and human
BON1 pancreatic cancer cells xenografted into nude mice
[40]. Hiyoshi et al. [27] reported that ouabain induced quies-
cence in neuroblastoma cells in vitro and a marked reduction
in tumor growth when human neuroblastoma cells were
xenografted into immune-deficient mice. Based on these
findings, the authors concluded that ouabain could be used in
chemotherapies to suppress tumor growth and/or arrest cells
to increase the therapeutic index in combination therapies.
Tailler et al. [18] identified the cardiac glycoside ouabain
as a potential antileukemic compound. They observed that
ouabain was highly efficient in inhibiting the growth of
human acute myeloid leukemia cells xenotransplanted in
immunodeficient mice, without exerting significant toxic-
ity on the host. The authors concluded that ouabain was
a promising antileukemic agent whose activity should be
evaluated in prospective clinical studies [18].
UNBS1450. Mijatovic et al. [41] investigated the in vitro and
in vivo anticancer activity of UNBS1450, a semisynthetic
derivative of the natural cardenolide UNBS1244 (isolated
from the African plant Calotropis procera). They observed
that UNBS1450 was able to inhibit cell growth of four
different non-small cell lung cancer cells (A549, NCI-H727,
A427, and CAL-12T) at nanomolar concentrations. This
cardenolide also significantly decreased tumor growth in
nude mice xenografted with human NCI-H727 cancer cells
and increased the survival rates in mice xenografted with
human A549 cancer cells. The authors observed in another
study [42] that the cytotoxic potency of UNBS1450 in A549
lung cancer cells was similar than that of the anticancer drugs
paclitaxel and SN38 (the active metabolite of irinotecan)
and much higher than that of cisplatin, carboplatin, and
oxaliplatin. UNBS1450 also decreased tumor growth in mice
xenotransplanted with A549 lung cancer cells and human
NCI-H727 lung cancer cells [42]. Another study revealed
that UNBS1450 inhibited the proliferation of human prostate
cancer cells (LNCaP, PC-3, and DU145) and increased the
survival of mice transplanted with human PC-3 prostate can-
cer cells [43]. Lefranc et al. [44] reported that UNBS1450 was
more cytotoxic on human glioblastoma cells (U373-MG and
T98G) than on human normal fibroblasts (WI-38 and WSI)
at nanomolar concentrations. This compound also inhibited
the proliferation of rat C6 glioblastoma cells at micromolar
concentrations. UNBS1450 increased the survival of mice
grafted with human U373-MG glioblastomas cells, without
observable toxic effects on the animals. Mathieu et al. [45]
reported that UNBS1450 blocked cell proliferation in several
human melanoma cell lines in vitro (IC
50
values between 5
and 45 nM) and improved the survival of immunodeficient
mice grafted with human VM-48melanoma brain metastasis
cells.
Periplocin. Lu et al. [46] reported that the natural cardenolide
periplocin induced similar cytotoxicity against a panel of
human lung cancer cell lines than against a rodent lung cancer
cell line (LL/2).They also observed antitumor activity inmice
transplanted with both the human A549 lung cancer cell
line and the murine LL/2 Lewis lung cancer cell line. Cheng
et al. [47] have recently reported that periplocin displayed a
potent cancer cell growth inhibitory activity in vitro and in
vivo. Periplocin inhibited cell growth of humanHA22T/VGH
hepatocellular carcinoma with an IC
50
of 27 nM and was less
toxic to normal peripheral blood mononucleated cells. The
authors also observed that periplocin showed an inhibition
of tumor growth when human Huh-7 hepatoma cells were
injected into immunodeficient mice, without observing clear
side effects on the host.
Lanatoside C. Badr et al. [48] identified the cardenolide
lanatoside C as a sensitizer of glioblastoma cells to tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL)-
induced cell death. They observed that lanatoside C, alone or
in combination with TRAIL, reduced tumor growth in nude
mice harboring human U87 glioblastoma cells.
Bufalin. Chen et al. [49] identified the bufadienolide bufalin
as a potential agent for the treatment of pancreatic cancer in
combination with the standard anticancer drug gemcitabine.
They found that bufalin inhibited the growth on three pancre-
atic cancer cell lines (Bxpc-3, Mia PaCa-2, and Panc-1) and
it synergistically increased gemcitabine-induced cancer cell
growth inhibition and apoptosis. The combination of bufalin
with gemcitabine was also found to significantly reduce
tumor growth in mice bearing humanMia Paca-2 pancreatic
cancer cells. Xie et al. [50] investigated the in vitro and in
vivo antiosteosarcoma activity of bufalin. They observed that
bufalin strongly inhibited the cell growth of different human
osteosarcoma cell lines, including the methotrexate-resistant
U2OS/MTX300 cell line. They also found that the treatment
with bufalin induced significant tumor growth inhibition
in mice xenotransplanted with the human U2OS/MTX300
osteosarcoma cell line, without decreasing the body weight
of the animals. The authors concluded that bufalin might be
an alternative chemotherapeutic agent to treat osteosarcoma,
particularly in methotrexate-resistant cancers [50]. Wang
et al. [19] have recently reported that bufalin was a potent
inhibitor of the steroid receptor coactivators SRC-3 and SRC-
1. Because these coactivators have been implicated in cancer
progression, the authors investigated whether bufalin could
also block cancer cell growth in cell culture and animal
models. They observed that bufalin inhibited the growth of
human MCF-7 breast cancer cells and human A549 lung
cancer cells at nanomolar concentrations (3–5 nM); these
concentrations also resulted in inhibition of the steroid
6 BioMed Research International
receptor coactivator SRC-3 and were below those reported
to be tolerated by humans (8.75 nM). They also found that
bufalin inhibited tumor growth in mice xenotransplanted
with human MDA-MB-231 breast cancer cells.
Arenobufagin. Zhang et al. [28] recently observed that the
bufadienolide arenobufagin induced a potent cell growth
inhibitory activity on cancer cells both in vitro and in
vivo. They tested its anticancer activity on several human
cancer cell lines (hepatoma, breast adenocarcinoma, cervix
adenocarcinoma, lung cancer, colon cancer, leukemia, and
gastric adenocarcinoma). Arenobufagin inhibited the growth
of all cancer cell lines at nanomolar concentrations, includ-
ing multidrug-resistant cancer cell lines. Arenobufagin also
inhibited the growth of human HepG2/ADM hepatocellular
carcinoma cells xenografted into immunodeficient mice,
without causing side effects on the hosts. The authors con-
cluded that their results may provide a rationale for future
clinical application using arenobufagin as a chemotherapeu-
tic agent for the treatment of patients with hepatocarcinoma
[28].
Bufotalin. Zhang et al. [51] observed that four bufadienolides
from Venenum Bufonis, a traditional Chinese medicine,
displayed inhibitory effects on the growth of human HepG2
hepatocarcinoma cells and human R-HepG2 multidrug hep-
atocarcinoma cells. One of them, bufotalin, was also able
to significantly inhibit the growth of human R-HepG2 cells
xenografted into immunodeficient mice, without observing
any life-threatening toxicity in the animals. The authors
discussed the fact that their study supports the possible
development of bufotalin as a potential agent in the treatment
of multidrug resistant hepatocellular carcinoma [51].
Data from preclinical studies reporting antitumor effects
in rodent xenografts of plant extracts containing cardiac
glycosides may also need reinterpretation. For instance,
Han et al. [52] reported that an extract from the plant
Streptocaulon juventas induced a strong inhibitory effect
on the proliferation of human lung A549 adenocarcinoma
cells. A bioassay-guided fractionation revealed that the most
cytotoxic fraction in vitro also induced antitumor effects in
athymic nude mice transplanted with human A549 cancer
cells without exerting side effects on the mice. Following
HPLC and NMR spectrometry, the main components of
this active fraction were identified as the cardiac glycosides
digitoxigenin, periplogenin, and periplogenin glucoside [52].
3. Possible Approaches to Reveal the Cancer
Therapeutic Potential of Cardiac Glycosides
in Preclinical Studies
As discussed before, the key feature of an efficient anticancer
drug candidate is its ability to kill (or to inhibit the pro-
liferation of) human cancer cells at concentrations that do
not significantly affect human nonmalignant cells. Ideally, the
drug candidate should kill all the cancer cells of the patients
without significantly affecting their normal cells. Because this
is difficult to achieve, one can settle for less. A drug that
improves the ability of our current anticancer drugs to kill
cancer cells at concentrations that do not significantly affect
nonmalignant cells could be therapeutically useful.
In vitro, one can evaluate whether the drug candidate
improves the selective cytotoxicity of the standard anticancer
drugs towards cancer cells by using the following approach.
The first step in this approach is the selection of a panel of
human cancer cell lines and human nonmalignant cell lines
(or primary cells). Because the cytotoxicity of some drugs
depends on the nature of the tissue fromwhich they originate,
one should select nonmalignant cell lines of the same tissue
origin than that of the selected cancer cell lines. A small
number of cancer cell lines may be sufficient to reveal the
therapeutic potential of a drug for a particular type of cancer.
However, the selection of a low number of nonmalignant cell
lines reduces the chances of finding toxicity on a specific
tissue that would limit the possible therapeutic use of the
drug. The next step is to treat the selected cell lines with
several concentrations of the drug candidate and of the
anticancer drugsmost commonly used in the treatment of the
selected cancers. Then, cell viability or cell death is estimated
with a cytotoxicity test (e.g., SRB assay and MTT assay), and
cytotoxic parameters (e.g., IC
50
values) are calculated. The
following step is to calculate one or several selectivity indexes
for the drug candidate and for the anticancer drug. These
selectivity indexes can be calculated by dividing the IC
50
values in the nonmalignant cell lines by the IC
50
values in the
cancer cell lines. For instance, if themean IC
50
value of a drug
in a variety of nonmalignant cells originated from several
tissues is 100 𝜇M and the mean IC
50
value of the drug in
several cell lines derived from a specific cancer is 20𝜇M, the
selectivity index for this particular cancer would be 5. Finally,
the following question must be answered: is the selectivity
index of the drug candidate higher (or at least similar) than
that of the standard anticancer drug? If the answer is no,
the drug candidate does not have therapeutic potential and
should not be tested in animal models. If the answer is yes,
the drug candidate has chemotherapeutic potential, which
should be confirmed by using in vivo experiments.
Rodent xenograft models are the most common animal
models used by researchers to evaluate the therapeutic
potential of anticancer drug candidates in vivo. However, as
discussed before, these models may be inadequate to evaluate
the therapeutic potential of cardiac glycosides. To the authors’
knowledge, all cardiac glycosides tested in human cells and
rodent nonmalignant cells have shown greater than 100-
fold higher toxicity towards the human cells in comparison
to the rodent cells. This does not mean, however, that all
compounds having the basic chemical structure of cardiac
glycosides (a steroid skeleton with an unsaturated lactone
ring) will be more toxic against human cells than against
rodent cells. One can test the suitability of using tumor
xenografts to evaluate the in vivo therapeutic potential of a
particular cardiac glycoside by testing if the cytotoxicity of
the cardiac glycoside against a panel of human nonmalignant
cells is similar than that against a panel of rodent nonmalig-
nant cells. If the compound behaves similarly in both types
of cell lines, its in vivo anticancer activity can be evaluated
in mice xenografted with human cancer cells. If the rodent
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cell lines are more resistant than the human cell lines to
the cytotoxicity of the cardiac glycoside, these models are
probably inadequate to evaluate its anticancer effects in vivo.
Animal models using mice transplanted with mouse cancer
cells may also be inadequate when human cells are more
sensitive than rodent cells to the cytotoxicity of the cardiac
glycoside.The reason is that the therapeutic target responsible
for the death of the human cells may be different than that
responsible for the death of the rodent cells and, therefore,
results obtained in mice may not be extrapolated to humans.
The anticancer activity of cardiac glycosides displaying
a similar cytotoxic profile in nonmalignant cells originated
from both human andmouse tissues can be assessed by using
tumor xenografts or other rodent models. It is important
to remember that most cancer patients requiring therapy
with anticancer drugs have metastatic disease and patient
survival is the parameter used by oncologists as an endpoint
of clinical interventions designed to assess drug efficacy
in patients with cancer (other parameters used by many
preclinical researchers as an endpoint for their experiments,
such as measurements of tumor volumes, do not necessarily
predict survival). It is essential, therefore, to select animal
models of metastasis and to assess animal survival as an
endpoint for the experiments. In our opinion, animals with
metastasis should be treated with equitoxic concentrations
of the cardiac glycoside and of the standard anticancer drug
used in the type of cancer under study. Then, one should
evaluate whether the cardiac glycoside improves the survival
rates induced by the standard anticancer drug. If the cardiac
glycoside improves (or at least matches) the selectivity index
(in vitro) and the survival rates (in vivo) of the standard
anticancer drugs, it should be considered for clinical trials
testing.
Rodent models are inappropriate for testing the anti-
cancer activity of cardiac glycosides that kill human non-
malignant cells at lower concentrations than those required
to kill rodent nonmalignant cells. These models, however,
could provide information on the pharmacokinetics of the
cardiac glycoside.Thesemodels may also help detect possible
toxicity not detected by using a panel of humannonmalignant
cell lines; they could help detect toxicity not mediated by
inhibition of the Na+/K+-ATPase (which seems to be the
main determinant for the species differences in sensitivity
to cardiac glycosides). In our opinion, a cardiac glycoside
that kills human nonmalignant cells at lower concentrations
than rodent nonmalignant cells should pass the following
tests before being considered for evaluation in clinical trials.
First, it shouldmatch or improve the selectivity indexes of the
standard anticancer drugs when they are evaluated in a panel
of human cancer cell lines derived from a particular type
of cancer versus a variety of human nonmalignant cell lines
and primary cells derived from a variety of human tissues.
Second, in vivo experiments (e.g., rodent models) should
exclude pharmacokinetic and toxicological limitations that
may compromise the in vivo anticancer activity of the cardiac
glycoside. Finally, if the cardiac glycoside is in clinical use
for the management of other diseases or if clinical data
already exist on its plasma and tissue concentrations, one
should also consider whether the anticancer effects observed
in preclinical studies may occur at concentrations within or
below the concentration range tolerated by humans.
4. Conclusion
Preclinical research has shown that cardiac glycosides can
both inhibit cancer cell proliferation at very low concen-
trations and induce potent anticancer effects in mice trans-
planted with human cancer cells. Based on these observa-
tions, cardiac glycosides have been considered as potential
anticancer drug candidates that should be evaluated in
clinical studies. This paper has reviewed evidence indicating
that cardiac glycosides may not selectively inhibit the prolif-
eration of human cancer cells and these compounds have the
ability of killing human cells at concentrations much lower
than those required to kill rodent cells (approximately 100–
1000 fold). This strongly suggests that the potent anticancer
effects induced by cardiac glycosides in mice transplanted
with human cancer cells may be an experimental artifact
caused by their ability to selectively kill human cells versus
rodent cells rather than by their ability to kill human cancer
cells versus human nonmalignant cells. It has also been
discussed that inhibition of cancer cell proliferation at low
concentrations is not an adequate parameter to predict the
therapeutic potential of a drug candidate. The key feature of
an efficient anticancer drug is its ability to kill (or inhibit the
proliferation of) human cancer cells at concentrations that
do not significantly affect human nonmalignant cells. Based
on this principle, an approach to evaluate the therapeutic
potential of cardiac glycosides in preclinical in vitro studies
has been proposed. This approach is also based on the
idea that only drug candidates that match or improve the
ability of the approved anticancer drugs to kill human cancer
cells at concentrations that do not significantly affect human
nonmalignant cells have a chance to be ultimately used in
cancer therapy. A test for revealing the suitability of using
rodent models for the evaluation of the anticancer activities
of cardiac glycosides in vivo has also been proposed. If the
cardiac glycoside passes this test, several recommendations
have been made for the evaluation of its cancer therapeutic
potential in these models. If the cardiac glycoside fails to pass
this test, an alternative approach for revealing its possible
therapeutic potential has been discussed. It is the hope of
the authors that this paper may help researchers evaluate
the therapeutic potential of cardiac glycosides in preclinical
studies.
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